source
- Evommune pays $30 million upfront to license Hinova’s oral molecular glue degrader for autoimmune pipelineEvommune announced a deal with Hinova Pharmaceuticals to license an oral molecular glue degrader aimed at autoimmune diseases. The agreement includes a $30 million upfront payment, split into $20…
- Novartis Lp(a) drug pelacarsen shows no cardiovascular benefit, raising doubts on Amgen and Lilly programsNovartis disclosed that its phase 3 Lp(a)Horizon trial of pelacarsen, an antisense oligonucleotide partnered with Ionis, failed to demonstrate any reduction in major cardiovascular events. The drug…